Heart and Vessels

, Volume 24, Issue 3, pp 219–227 | Cite as

Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats

  • Caroline Fernandes-Santos
  • Leonardo de Souza Mendonça
  • Carlos Alberto Mandarim-de-Lacerda
Original Article


Cardiovascular remodeling contributes to the progression of cardiovascular disease. Thus, our aim was to evaluate the action of long-term treatment with olmesartan on cardiac and aortic adverse remodeling and its relationship with blood pressure (BP) and tensile forces acting on the aortic wall. Five-month-old male rats were divided in: WKY group (n = 6), SHR group (n = 6), and SHRs treated with hydralazine 30 mg/kg/day (SHR-H, n = 8) or olmesartan 10 mg/kg/day (SHR-O, n = 8). Medications were administered for 16 weeks. The SHR group showed hypertension (189 ± 4 mmHg), cardiomyocyte hypertrophy (+107%), interstitial fibrosis (5.7% vs 1.9% in WKY), and reduced intramyocardial vascularization (9.1% vs 22.8% in WKY). In aorta, the SHRs showed outward hypertrophic remodeling, increased elastic fibers content (+36%), and increased circumferential wall tension (CWT, 2.79 × 104 dyne/cm) and tensile stress (TS, 261.4 × 104 dyne/cm2). Hydralazine and olmesartan decreased BP (−45% approximately) and likewise CWT and TS (−45% and −35% approximately). Both medications prevented left ventricle remodeling, but olmesartan improved cardiomyocyte hypertrophy better than hydralazine. Hydralazine did not alter media hypertrophy, but it enlarged lumen diameter and increased elastic fibers. It is unlikely that olmesartan prevented all aortic alterations. Taken together, long-term control of BP alone is not sufficient to prevent aortic remodeling due to hypertension, but in myocardium it seems to be enough, except for cardiomyocyte hypertrophy. The differential action of olmesartan suggests that it is essential to block growth stimulation by angiotensin II in cardiomyocytes and vascular smooth muscle cells in order to better prevent cardiovascular adverse remodeling due to arterial hypertension.

Key words

Angiotensin II AT1 receptor Renin-angiotensin system Arterial hypertension Arterial wall stress 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tronc F, Wassef M, Esposito B, Henrion D, Glagov S, Tedgui A (1996) Role of NO in flow-induced remodeling of the rabbit common carotid artery. Arterioscler Thromb Vasc Biol 16:1256–1262PubMedGoogle Scholar
  2. 2.
    Touyz RM (2000) Molecular and cellular mechanisms regulating vascular function and structure — implications in the pathogenesis of hypertension. Can J Cardiol 16:1137–1146PubMedGoogle Scholar
  3. 3.
    Erzen B, Sabovic M, Sebestjen M, Poredos P (2007) Endothelial dysfunction, intima-media thickness, ankle-brachial pressure index, and pulse pressure in young post-myocardial infarction patients with various expressions of classical risk factors. Heart Vessels 22:215–222PubMedCrossRefGoogle Scholar
  4. 4.
    Paul M, Poyan Mehr A, Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86:747–803PubMedCrossRefGoogle Scholar
  5. 5.
    Unger T (2002) The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89:3A–9APubMedCrossRefGoogle Scholar
  6. 6.
    Otsui K, Inoue N, Kobayashi S, Shiraki R, Honjo T, Takahashi M, Hirata K, Kawashima S, Yokoyama M (2007) Enhanced expression of TLR4 in smooth muscle cells in human atherosclerotic coronary arteries. Heart Vessels 22:416–422PubMedCrossRefGoogle Scholar
  7. 7.
    Brousil JA, Burke JM (2003) Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther 25:1041–1055PubMedCrossRefGoogle Scholar
  8. 8.
    Ball KJ, Williams PA, Stumpe KO (2001) Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl 19:S49–S56PubMedGoogle Scholar
  9. 9.
    Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J (2001) Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 3:283–291, 318CrossRefGoogle Scholar
  10. 10.
    Weibel ER (1979) Stereological methods. Practical methods for biological morphometry. Vol. 1. Academic Press, London New York Toronto Sydney San Francisco, p. 415Google Scholar
  11. 11.
    Yin FC, Spurgeon HA, Rakusan K, Weisfeldt ML, Lakatta EG (1982) Use of tibial length to quantify cardiac hypertrophy: application in the aging rat. Am J Physiol 243:H941–H947PubMedGoogle Scholar
  12. 12.
    Mandarim-de-Lacerda CA (2003) Stereological tools in biomedical research. An Acad Bras Cienc 75:469–486PubMedGoogle Scholar
  13. 13.
    Bezerra DG, Lacerda Andrade LM, Pinto da Cruz FO, Mandarimde-Lacerda CA (2008) Atorvastatin attenuates cardiomyocyte loss in adult rats from protein-restricted dams. J Card Fail 14:151–160PubMedCrossRefGoogle Scholar
  14. 14.
    Sterio DC (1984) The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 134:127–136PubMedGoogle Scholar
  15. 15.
    Fullmer HM, Lillie RD (1956) A selective stain for elastic tissue (orcinol-new fuchsin). Stain Technol 31:27–29PubMedGoogle Scholar
  16. 16.
    Carallo C, Irace C, Pujia A, De Franceschi MS, Crescenzo A, Motti C, Cortese C, Mattioli PL, Gnasso A (1999) Evaluation of common carotid hemodynamic forces. Relations with wall thickening. Hypertension 34:217–221PubMedGoogle Scholar
  17. 17.
    Prado CM, Ramos SG, Alves-Filho JC, Elias J Jr, Cunha FQ, Rossi MA (2006) Turbulent flow/low wall shear stress and stretch differentially affect aorta remodeling in rats. J Hypertens 24:503–515PubMedCrossRefGoogle Scholar
  18. 18.
    Okamoto K, Tabei R, Fukushima M, Nosaka S, Yamori Y (1966) Further observations of the development of a strain of spontaneously hypertensive rats. Jpn Circ J 30:703–716PubMedGoogle Scholar
  19. 19.
    Pfeffer JM, Pfeffer MA, Fishbein MC, Frohlich ED (1979) Cardiac function and morphology with aging in the spontaneously hypertensive rat. Am J Physiol 237:H461–H468PubMedGoogle Scholar
  20. 20.
    Engelmann GL, Vitullo JC, Gerrity RG (1987) Morphometric analysis of cardiac hypertrophy during development, maturation, and senescence in spontaneously hypertensive rats. Circ Res 60: 487–494PubMedGoogle Scholar
  21. 21.
    Bing OH, Brooks WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE, Sen S, Conrad CH (1995) The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol 27:383–396PubMedCrossRefGoogle Scholar
  22. 22.
    Okazaki H, Minamino T, Tsukamoto O, Kim J, Okada K, Myoishi M, Wakeno M, Takashima S, Mochizuki N, Kitakaze M (2006) Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition. Hypertens Res 29:277–284PubMedCrossRefGoogle Scholar
  23. 23.
    Tsotetsi OJ, Woodiwiss AJ, Netjhardt M, Qubu D, Brooksbank R, Norton GR (2001) Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats. Hypertension 38:846–851PubMedCrossRefGoogle Scholar
  24. 24.
    Neves MF, Virdis A, Schiffrin EL (2003) Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism. J Hypertens 21:189–198PubMedCrossRefGoogle Scholar
  25. 25.
    van Wamel AJ, Ruwhof C, van der Valk-Kokshoom LE, Schrier PI, van der Laarse A (2001) The role of angiotensin II, endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy. Mol Cell Biochem 218:113–124PubMedCrossRefGoogle Scholar
  26. 26.
    Masawa N, Glagov S, Zarins CK (1994) Quantitative morphologic study of intimal thickening at the human carotid bifurcation: II. The compensatory enlargement response and the role of the intima in tensile support. Atherosclerosis 107:147–155PubMedCrossRefGoogle Scholar
  27. 27.
    Cotta-Pereira G, Rodrigo FG, David-Ferreira JF (1977) The elastic system fibers. Adv Exp Med Biol 79:19–30PubMedGoogle Scholar
  28. 28.
    Kwon JS, Lee SJ, Kim YG, Bae JW, Hwang KK, Cho MC, Kim DW (2006) Effect of pressure overload and its recovery on the rat carotid artery: change of vascular reactivity and remodeling process. Heart Vessels 21:48–55PubMedCrossRefGoogle Scholar
  29. 29.
    deBlois D, Tea BS, Than VD, Tremblay J, Hamet P (1997) Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 29:340–349PubMedGoogle Scholar
  30. 30.
    Tea BS, Dam TV, Moreau P, Hamet P, deBlois D (1999) Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. Hypertension 34:229–235PubMedGoogle Scholar
  31. 31.
    Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM (2005) Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1–7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289:H1013–H1019PubMedCrossRefGoogle Scholar
  32. 32.
    Ferrante F, Abbate F, Ciriaco E, Laura R, Amenta F (1994) Influence of isradipine treatment on the morphology of the aorta in spontaneously hypertensive rats. J Hypertens 12:523–531PubMedCrossRefGoogle Scholar
  33. 33.
    Albaladejo P, Bouaziz H, Duriez M, Gohlke P, Levy BI, Safar ME, Benetos A (1994) Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats. Hypertension 23: 74–82PubMedGoogle Scholar
  34. 34.
    Bezie Y, Lamaziere JM, Laurent S, Challande P, Cunha RS, Bonnet J, Lacolley P (1998) Fibronectin expression and aortic wall elastic modulus in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 18:1027–1034PubMedGoogle Scholar
  35. 35.
    Mendonca LS, Fernandes-Santos C, Mandarim-de-Lacerda CA (2007) Cardiac and aortic structural alterations due to surgically-induced menopause associated with renovascular hypertension in rats. Int J Exp Pathol 88:301–309CrossRefGoogle Scholar
  36. 36.
    Brosnan MJ, Hamilton CA, Graham D, Lygate CA, Jardine E, Dominiczak AF (2002) Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 20: 281–286PubMedCrossRefGoogle Scholar
  37. 37.
    Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M (2005) Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 45:545–551PubMedCrossRefGoogle Scholar
  38. 38.
    Li Z, Chen XD, Ni SK, Li JW, Lin MS (2004) Olmesartan inhibits the expression of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha and improves vascular remodeling after vascular injury in mouse. Chin J Traumatol 7:56–61PubMedGoogle Scholar
  39. 39.
    Fliser D, Buchholz K, Haller H (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110:1103–1107PubMedCrossRefGoogle Scholar
  40. 40.
    Miyazaki M Takai S (2002) Anti-atherosclerotic efficacy of olmesartan. J Hum Hypertens 16Suppl 2:S7–S12PubMedCrossRefGoogle Scholar
  41. 41.
    Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, de Gasparo M, Horiuchi M (2001) Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 104:2716–2721PubMedCrossRefGoogle Scholar
  42. 42.
    Wolf G, Wenzel UO (2004) Angiotensin II and cell cycle regulation. Hypertension 43:693–698PubMedCrossRefGoogle Scholar
  43. 43.
    de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415–472PubMedGoogle Scholar
  44. 44.
    Fukada SY, Tirapelli CR, de Godoy MA, de Oliveira AM (2005) Mechanisms underlying the endothelium-independent relaxation induced by angiotensin II in rat aorta. J Cardiovasc Pharmacol 45:136–143PubMedCrossRefGoogle Scholar
  45. 45.
    Yokoyama H, Averill DB, Brosnihan KB, Smith RD, Schiffrin EL, Ferrario CM (2005) Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens 18: 922–929PubMedCrossRefGoogle Scholar
  46. 46.
    Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM (2004) Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43:970–976PubMedCrossRefGoogle Scholar
  47. 47.
    Santos RA, Campagnole-Santos MJ, Andrade SP (2000) Angiotensin-(1–7): an update. Regul Pept 91:45–62PubMedCrossRefGoogle Scholar
  48. 48.
    Zhang M, Ma H, Wang BS, Zhao YZ (2006) Angiotensin II type 2 receptor gene polymorphisms and cardioprotective role in essential hypertension. Heart Vessels 21:95–101PubMedCrossRefGoogle Scholar
  49. 49.
    Schuijt MP, Basdew M, van Veghel R, de Vries R, Saxena PR, Schoemaker RG, Danser AH (2001) AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction. Am J Physiol Heart Circ Physiol 281:H2590–H2596PubMedGoogle Scholar
  50. 50.
    Akishita M, Iwai M, Wu L, Zhang L, Ouchi Y, Dzau VJ, Horiuchi M (2000) Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 102:1684–1689PubMedGoogle Scholar

Copyright information

© Springer Japan 2009

Authors and Affiliations

  • Caroline Fernandes-Santos
    • 1
  • Leonardo de Souza Mendonça
    • 1
  • Carlos Alberto Mandarim-de-Lacerda
    • 1
  1. 1.Laboratory of Morphometry and Cardiovascular Morphology, Biomedical Center, Institute of BiologyState University of Rio de JaneiroRio de JaneiroBrazil

Personalised recommendations